Alembic Pharmaceuticals Limited (APLLTD.NS)
- Previous Close
958.00 - Open
961.95 - Bid --
- Ask --
- Day's Range
955.80 - 1,010.00 - 52 Week Range
542.40 - 1,094.00 - Volume
136,388 - Avg. Volume
175,198 - Market Cap (intraday)
196.072B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
33.26 - EPS (TTM)
29.99 - Earnings Date May 9, 2024
- Forward Dividend & Yield 8.00 (0.84%)
- Ex-Dividend Date Jul 28, 2023
- 1y Target Est
862.25
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
alembicpharmaceuticals.com14,593
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: APLLTD.NS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLLTD.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLLTD.NS
Valuation Measures
Market Cap
186.90B
Enterprise Value
194.00B
Trailing P/E
31.91
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.16
Price/Book (mrq)
4.21
Enterprise Value/Revenue
3.25
Enterprise Value/EBITDA
21.51
Financial Highlights
Profitability and Income Statement
Profit Margin
9.65%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
61.18B
Net Income Avi to Common (ttm)
5.9B
Diluted EPS (ttm)
29.99
Balance Sheet and Cash Flow
Total Cash (mrq)
1.48B
Total Debt/Equity (mrq)
19.44%
Levered Free Cash Flow (ttm)
--
Research Analysis: APLLTD.NS
Company Insights: APLLTD.NS
APLLTD.NS does not have Company Insights